CCL7+ Macrophages Drive Immunotherapy Resistance in Colorectal Cancer

Study Background and Research Question

Colorectal cancer (CRC) remains one of the most prevalent and deadly malignancies globally, with immune checkpoint inhibitors (ICIs) showing limited efficacy for most patients. While ICIs, particularly PD-1/PD-L1 inhibitors, have transformed treatment for subsets of CRC patients with high microsatellite instability or mismatch repair deficiency, up to 50% of these patients still do not respond to immunotherapy, leading to progression and recurrence (source: Chen et al., 2025). The cellular and molecular underpinnings of this resistance have not been fully elucidated. Notably, tumor-associated macrophages (TAMs) are known to influence the tumor immune microenvironment, but the mechanisms by which specific TAM subsets mediate immunotherapy resistance in CRC have remained obscure.

Key Innovation from the Reference Study

The centerpiece of the referenced study by Chen et al. is the identification of CCL7+ TAMs as key regulators of ICI resistance in CRC. Elevated levels of these macrophages in tumor tissues are tightly correlated with immunotherapy tolerance. Mechanistically, the authors demonstrate that myeloid cell-intrinsic CCL7 orchestrates both the accumulation and immunosuppressive function of TAMs, while simultaneously suppressing the infiltration of activated CD8+ T cells. This dual role underscores CCL7 as a promising target for overcoming resistance to immune checkpoint blockade in CRC (source: Chen et al., 2025).

Methods and Experimental Design Insights

To dissect the function of CCL7 in CRC, the researchers developed myeloid cell-specific Ccl7 knockout mice and established MC38 tumor-bearing mouse models. An integrative approach combined proteomic profiling, RNA sequencing, and flow cytometry to characterize immune cell populations within the tumor microenvironment. These methods allowed for precise dissection of the molecular pathways and cellular dynamics underpinning CCL7's role. Importantly, knockout of CCL7 in myeloid cells enabled direct assessment of its impact on TAM recruitment, phenotype, and the migration of effector CD8+ T cells.

Protocol Parameters

• assay | flow cytometry analysis | value_with_unit | cell-type quantification (no unit) | applicability | quantifying TAM and CD8+ T cell infiltration in tumor tissue | rationale | essential for immune profiling post-CCL7 modulation | source_type | paper
• assay | Ccl7 myeloid-specific knockout | value_with_unit | genetic knockout (no unit) | applicability | mechanistic dissection of CCL7's function in myeloid cells | rationale | enables determination of cell-intrinsic effects | source_type | paper
• assay | MC38 tumor implantation | value_with_unit | 1x10⁶ cells/mouse | applicability | syngeneic CRC model in mice | rationale | standard preclinical CRC model for immunotherapy studies | source_type | paper
• assay | anti-PD-L1 antibody administration | value_with_unit | dosing as per model (not specified) | applicability | testing combinatorial immunotherapy efficacy | rationale | measures impact of CCL7 blockade on ICI responsiveness | source_type | paper
• assay | clodronate liposome injection | value_with_unit | 100–200 μL i.v./i.p. (workflow recommendation) | applicability | selective macrophage depletion in vivo | rationale | enables functional studies of TAM roles in CRC immunotherapy | source_type | workflow_recommendation

Core Findings and Why They Matter

The study provides several mechanistic insights:

• Elevated CCL7+ TAMs correlate with ICI resistance: Tumors with high levels of CCL7-expressing macrophages are more likely to exhibit poor responses to ICIs in both human CRC samples and mouse models (source: Chen et al., 2025).
• CCL7 drives TAM immunosuppressive metabolism: CCL7 enhances peroxisome biogenesis and fatty acid oxidation in TAMs via the PI3K–AKT–PEX3 axis, promoting an immunosuppressive phenotype.
• Suppression of CD8+ T cell infiltration: By inhibiting the AKT2–STAT1–CXCL10 pathway, CCL7+ TAMs reduce chemokine-driven recruitment of activated CD8+ T cells, further dampening antitumor immunity.
• Therapeutic potential of CCL7 blockade: Genetic deletion of CCL7 in myeloid cells reduces immunosuppressive TAMs, increases intratumoral CD8+ T cells, delays CRC progression, and enhances the efficacy of anti-PD-L1 therapy.

Collectively, these findings reveal a critical axis by which TAMs orchestrate immunotherapy resistance, highlighting CCL7 as a rational target for combinatorial strategies aimed at reversing immune evasion in CRC.

Comparison with Existing Internal Articles

Several internal resources provide practical and mechanistic guidance on macrophage depletion using Clodronate Liposomes. For example, the article "Strategic Macrophage Depletion: Mechanistic Insights and…" contextualizes the use of liposome-encapsulated clodronate as a tool for probing the functional roles of macrophages in models of cancer immunotherapy resistance. This aligns with the reference study's approach of modulating TAM populations to dissect their contribution to immune evasion. Other resources, such as "Clodronate Liposomes: Selective In Vivo Macrophage Depletion…" and "Strategic Macrophage Depletion: Mechanistic Insight and T…", reinforce the specificity and translational value of phagocytosis-mediated macrophage depletion in vivo. These articles, together with the reference study, support the broader paradigm of using macrophage-targeted interventions to interrogate and potentially overcome immunotherapy resistance in solid tumors.

Limitations and Transferability

While the study robustly demonstrates the role of CCL7+ TAMs in murine CRC models, there are important considerations for translational relevance. The mouse models employed (e.g., MC38 tumor line) recapitulate key features of CRC immunobiology but cannot fully mimic the heterogeneity of human tumors. The specific contribution of other myeloid cell subsets or non-immune stromal cells remains to be clarified. Furthermore, the impact of CCL7 targeting in the context of diverse immunotherapeutic regimens or in combinatorial settings with other immune modulators warrants systematic investigation (source: Chen et al., 2025). Reproducibility across different tumor models and genetic backgrounds should also be established.

Research Support Resources

For researchers aiming to model or modulate macrophage function in vivo, Clodronate Liposomes (SKU K2721) from APExBIO offer a validated approach for selective depletion of macrophages via phagocytosis-mediated delivery and apoptosis induction. This reagent enables investigators to experimentally dissect the roles of TAMs in immune cell modulation, as illustrated in both the reference study and internal thought-leadership articles. When deploying Clodronate Liposomes, investigators are encouraged to employ appropriate controls (e.g., PBS Liposomes) and tailor dosing regimens to their specific experimental models (workflow_recommendation). For in-depth protocol optimization and strategic study design, internal resources such as "Scenario-Driven Best Practices for Clodronate Liposomes" provide actionable guidance for robust macrophage depletion workflows.